Abramson Cancer Center
Clinical Trials
427
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (327 trials with phase data)• Click on a phase to view related trials
Head Stabilization of Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT07116759
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
FTT PET/CT in Pancreatic Neuroendocrine Tumors
- Conditions
- Neuroendocrine Carcinoma MetastaticPancreatic Tumors
- Interventions
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT07114939
- Locations
- 🇺🇸
University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Telehealth Collaborative Care Model (CoCM) in Lung Cancer
- Conditions
- Lung Cancer (Diagnosis)AnxietyDepression in Adults
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT07102147
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver
- Interventions
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT07082439
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology
- Conditions
- Ovarian Cancer
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 240
- Registration Number
- NCT07078409
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 86
- Next
News
Nivolumab Fails to Improve pCR Rate in Esophageal Adenocarcinoma: ECOG-ACRIN EA2174 Trial
The phase 2/3 ECOG-ACRIN EA2174 trial showed that adding nivolumab to neoadjuvant chemoradiation did not significantly improve pathologic complete response (pCR) rates in patients with locoregional esophageal adenocarcinoma.